For the treatment of glaucoma, drug retention and infiltration are areas that needs to be focused on. Nanoparticles offer significant advantages in protecting the drug from degradation and maintaining its structural integrity. Nanoparticles are also capable of increasing the penetration of drugs through the ocular barrier. Therefore, nanoparticle-based drug delivery systems have potential applications in the ocular treatment of glaucoma.
The introduction of new site-specific drug delivery systems may be a solution for glaucoma. Ace Therapeutics offers development services for nanoparticle delivery systems composed of various types of polymers and is committed to developing nano-delivery vehicles that improve barrier permeability and slow release of drugs for researchers and pharmaceutical companies.
Nanotechnology-Based Delivery System for Glaucoma
Nanoparticles are spherical colloidal structures that can be made from a variety of materials. Examples include polymers, inorganic materials, proteins, lipids, etc. Nanoparticles are capable of delivering sufficient amount of drug to the target tissue in the eye to overcome the ocular barrier. Therefore, this structure has become a common therapeutic carrier for glaucoma drug delivery. Common nanoparticles include polymeric nanoparticles, lipid nanoparticles, inorganic nanoparticles, etc. The figure below shows some of the various nanodrug delivery systems used for ocular tissues.
Fig. 1 Various nano drug delivery systems for ocular tissues. (Yadav K S, et al., 2019)
Compared to other ocular delivery systems, nanoparticles offer high encapsulation, high ocular permeability, protection against drug ocular toxicity, good stability and biocompatibility. They can be delivered by various routes, such as topical, transcorneal or subconjunctival routes.
Services for Nanoparticle Delivery System Development for Glaucoma
We offer services for the development of nanoparticle carriers of different material compositions, customizing our services for your specific needs.
Table 1. Our specific services for nanotechnology-based delivery system development for glaucoma.
| Specific Items | Our Services |
|---|---|
| Polymeric nanoparticles | We offer strategies for the development of polymeric nanoparticles consisting of polymers of synthetic or natural origin. Specific materials include, common synthetic polymers - polylactide, polycaprolactone, polyacrylate, polylactic-co-glycolic acid (PLGA), and common natural polymers - chitosan, alginate, gelatin, etc. |
| Lipid nanoparticles | We offer strategies for the development of solid lipid nanoparticles (SLN), nanostructured lipid carriers (NLCs), and the investigation and evaluation of their application as carriers for the encapsulation of anti-glaucoma drugs. These solutions offer advantages such as sustained drug release, excellent biocompatibility. We improve carrier performance by using innovative measures such as mixtures of polymer and lipid nanoparticles, nanoparticles made from a mixture of solid and liquid lipids, and surface modifications. |
| Inorganic nanoparticles | We exploit the inherent properties of inorganic nanoparticles applied in glaucoma drug therapy, such as gold nanoparticles (GNP), mesoporous silica nanoparticles (MSN). The focus of attention is to assess the cytotoxic and cumulative toxic effects of inorganic nanoparticles. |
Your Nanoparticle-Incorporated Drug
Different glaucoma drugs can be incorporated into different types of nanoparticles, and the choice of which type of nanoparticles depends on the choice of drug. Some of the commonly used polymeric nanoparticles for drugs include,
- Pilocarpine
- brimonidine tartrate
- Timolol maleate
- Dorzolamide hydrochloride
Our mission is to formulate a novel, sustained drug delivery system to combat glaucoma. Regardless of the type of nanoparticle carrier, and regardless of the stage of development, please contact us to help you establish and validate a drug delivery system whenever you need our assistance.
References
- Yadav K S, et al. Glaucoma: Current treatment and impact of advanced drug delivery systems. Life Sciences, 2019.
- El Hoffy N M, et al. Glaucoma: management and future perspectives for nanotechnology-based treatment modalities. European Journal of Pharmaceutical Sciences, 2021, 158: 105648.